---
title: "Skyrizi (risankizumab-rzaa) in plaque psoriasis: Indication questions"
description: "Indication questions on Skyrizi (risankizumab-rzaa) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names. Questions: What is Skyrizi approved for in plaque psoriasis? What is the generic name for Skyrizi? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/indication"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa) in plaque psoriasis: Indication questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)

Questions that apply to every indication of Skyrizi are on [Skyrizi (risankizumab-rzaa), all indications](https://www.evicenter.com/medical-information/skyrizi).

## Indication

<a id="skyrizi-indication"></a>

### What is Skyrizi approved for in plaque psoriasis?

> “SKYRIZI<sup>®</sup> is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and 
> pediatric patients 6 years of age and older who are candidates for systemic therapy or 
> phototherapy.”

Source: [SKYRIZI: Prescribing information, page 3, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=3)

Note: The label also lists active psoriatic arthritis, Crohn’s disease, and ulcerative colitis as separate indications.

## Drug names

<a id="skyrizi-generic-name"></a>

### What is the generic name for Skyrizi?

> “SKYRIZI<sup>®</sup> (risankizumab-rzaa) injection, for subcutaneous or 
> intravenous use”

Source: [SKYRIZI: Prescribing information, page 1, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=1)

> “Risankizumab-rzaa, an interleukin-23 (IL-23) antagonist, is a humanized immunoglobulin G1 
> (IgG1) monoclonal antibody. Risankizumab-rzaa is produced by recombinant DNA technology 
> in Chinese hamster ovary cells and has an approximate molecular weight of 149 kDa.”

Source: [SKYRIZI: Prescribing information, page 17, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=17)

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/access-and-coverage)
